Difference between revisions of "Vortioxetine-agomelatine"
From Psychiatrienet
| Line 9: | Line 9: | ||
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref> | * '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref> | ||
| − | |info = * References <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> <ref name="Summary of Product Characteristics">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf</ref> | + | |info = * References <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> <ref name="Summary of Product Characteristics"> [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf Summary of Product Characteristics]</ref> |
}} | }} | ||
Revision as of 10:21, 22 September 2016
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from Vortioxetine to agomelatine.[1] [2]
Stop Vortioxetine - Day 1: reduce dosage of vortioxetine to 5 mg/day.
- Day 8: stop administration of vortioxetine.
Start agomelatine- Day 9: start administration of agomelatine in a dosage of 25 mg/day.
- Day 23: if necessary, increase dosage of agomelatine to 50 mg/day.[3]
More information- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
- ↑ Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54
- ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "vortioxetine" (Dutch)
- ↑ Summary of Product Characteristics
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
